Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 8 of 8 publications.

Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012

Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04

Dine JL, Garimella SV, Gehlhaus K, Grandin M, Letwin D, Caplen N, Lipkowitz S. Gp78 is a negative regulator of TRAIL-induced apoptosis in breast cancer cells. Poster presented at the 106th Annual Meeting of the American Association for Cancer Research; April 2015. Philadelphia, PA. [abstract] Cancer Res. 2015 Aug; 75(15 Suppl):15. doi: 10.1158/1538-7445.AM2015-15

Sherrill B, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of Quality-of-Life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ Metastatic Breast Cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 2009. San Antonio, TX. [abstract] Cancer Res. 2009 Dec; 69(24 (Suppl)):5106. doi: 10.1158/0008-5472.SABCS-09-5106

Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009 Mar;69(6):2349-57.

Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006 Jan 15;66(2):1241-9.

Paramastri YA, Anthony MS, Wilkinson LM, Phifer BM, Cline JM. Dietary soy phytoestrogens inhibit tumor promotion by exogenous but not endogenous estrogens in the rat DMBA model of mammary carcinogenesis. Cancer Res. 2001 Mar;42(Suppl):310.

Suit HD, Sedlacek R, Wagner M, Orsi L, Silobrcic V, Rothman KJ. Effect of corynebacterium parvum on the response to irradiation of a c3h fibrosarcoma. Cancer Res. 1976 Apr 1;36(4):1305-14.